Impact of Baseline Best-Corrected Visual Acuity on Outcomes with Aflibercept 8 mg in Patients with Diabetic Macular Edema
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Aflibercept 8 mg demonstrated comparable visual and anatomic improvements versus 2 mg in patients with diabetic macular edema at week 96, regardless of baseline best-corrected visual acuity ≤20/50 versus ≥20/40.
Fields of Study & Subjects
Retinal Diseases and Treatments
Retinal and Macular Surgery
Ocular Diseases and Behçet’s Syndrome
Publication details
- Journal / source
- Ophthalmology Retina
- Volume
- 10
- Issue
- 8
- Pages
- 887–890
- Publication date
- 30 March 2026
- Language
- EN